Single-Agent Glasdegib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
A Phase 2, Double-Blind, Randomized Safety and Efficacy Study of Glasdegib (PF-04449913) versus Placebo in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Category & Conditions: Cancer
Medicine: DAURISMO TABLETS(GLASDEGIB)
ClinicalTrials.gov Identifier (NCT): NCT02226172
Protocol ID: B1371013
Open Plain Language Summary Result:
Click here